Equfina, a treatment for Parkinson's disease from Esai, can be prescribed in general hospitals. According to related industries, Equfina (Safinamide) has passed the drug committee (DC) of Seoul National University Hospital and Asan Medical Center among Big 5 medical institutions, and is undergoing landing procedures at major medical institutions.

According to the MOHW notice, it was applied health benefits as 'adjuvant therapy of Levodopa-containing drugs in patients with idiopathic Parkinson's disease with movement agitation symptoms'. Equfina was approved by the MFDS on June 24, 2020 as a once-a-day Levodopa supplemental therapy for Parkinson's disease patients. Equfina is a third-generation monoam